The use of faecal microbiota transplant as treatment for recurrent or refractory infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
Author
Mullish, Benjamin HMerrick, Blair
Quraishi, Mohammed Nabil
Bak, Aggie
Green, Christopher A
Moore, David J
Porter, Robert J
Elumogo, Ngozi T
Segal, Jonathan P
Sharma, Naveen
Marsh, Belinda
Kontkowski, Graziella
Manzoor, Susan E
Hart, Ailsa L
Settle, Christopher
Keller, Josbert J
Hawkey, Peter
Iqbal, Tariq H
Goldenberg, Simon D
Williams, Horace R T
Publication date
2024-06-06Subject
Gastroenterology
Metadata
Show full item recordAbstract
The first British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)-endorsed faecal microbiota transplant (FMT) guidelines were published in 2018. Over the past 5 years, there has been considerable growth in the evidence base (including publication of outcomes from large national FMT registries), necessitating an updated critical review of the literature and a second edition of the BSG/HIS FMT guidelines. These have been produced in accordance with National Institute for Health and Care Excellence-accredited methodology, thus have particular relevance for UK-based clinicians, but are intended to be of pertinence internationally. This second edition of the guidelines have been divided into recommendations, good practice points and recommendations against certain practices. With respect to FMT for Clostridioides difficile infection (CDI), key focus areas centred around timing of administration, increasing clinical experience of encapsulated FMT preparations and optimising donor screening. The latter topic is of particular relevance given the COVID-19 pandemic, and cases of patient morbidity and mortality resulting from FMT-related pathogen transmission. The guidelines also considered emergent literature on the use of FMT in non-CDI settings (including both gastrointestinal and non-gastrointestinal indications), reviewing relevant randomised controlled trials. Recommendations are provided regarding special areas (including compassionate FMT use), and considerations regarding the evolving landscape of FMT and microbiome therapeutics.Citation
Mullish BH, Merrick B, Quraishi MN, Bak A, Green CA, Moore DJ, Porter RJ, Elumogo NT, Segal JP, Sharma N, Marsh B, Kontkowski G, Manzoor SE, Hart AL, Settle C, Keller JJ, Hawkey P, Iqbal TH, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2024 Jun 6;73(7):1052-1075. doi: 10.1136/gutjnl-2023-331550.Type
ArticleOther
Additional Links
http://gut.bmj.com/PMID
38609165Journal
GutPublisher
British Medical Associationae974a485f413a2113503eed53cd6c53
10.1136/gutjnl-2023-331550